Mindmed reports third quarter 2022 financial results and business highlights

– initiated phase 2b dose-optimization trial in patients with generalized anxiety disorder, with first patients dosed in q3 2022 and key clinical readout expected in late 2023 – – advanced ind-enabling studies for mm-402 and initiated phase 1 investigator-initiated trial in q3 2022 –  – cash and cash equivalents of $154.5 million expected to fund current operating plan into first half of 2025 - – company to host conference call today at 8:30 am et – new york , nov. 10, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended september 30, 2022. "we are pleased with the progress made in the third quarter as we continue executing on our core development programs, mm-120 and mm-402, and accelerating preparations for phase 3 studies – all with the goal of bringing our treatments to market as efficiently as possible for the benefit of both patients and shareholders.
MNMD Ratings Summary
MNMD Quant Ranking